Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Accumulated Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Accumulated Expenses data on record, last reported at $2.2 million in Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 202.06% to $2.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.2 million, a 202.06% increase, with the full-year FY2025 number at $8.3 million, up 7335.14% from a year prior.
  • Accumulated Expenses reached $2.2 million in Q1 2026 per OLMA's latest filing, down from $8.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for OLMA hit a ceiling of $12.4 million in Q2 2023 and a floor of $111000.0 in Q4 2024.
  • A 5-year average of $2.4 million and a median of $1.1 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: plummeted 97.97% in 2024, then surged 7335.14% in 2025.
  • Tracing OLMA's Accumulated Expenses over 5 years: stood at $296000.0 in 2022, then skyrocketed by 1746.28% to $5.5 million in 2023, then tumbled by 97.97% to $111000.0 in 2024, then soared by 7335.14% to $8.3 million in 2025, then tumbled by 73.32% to $2.2 million in 2026.
  • Business Quant data shows Accumulated Expenses for OLMA at $2.2 million in Q1 2026, $8.3 million in Q4 2025, and $406000.0 in Q3 2025.